How long does Mounjaro take to start working?
Most patients see initial loss within 4-8 weeks; substantial loss as titration reaches 7.5-15 mg.
What is typical plateau timing?
Around week 40-60 for tirzepatide; later than semaglutide.
Should I increase my dose?
Discuss with your prescriber; dose escalation is the most common next step.
Does Mounjaro stop working over time?
True tolerance is uncommon; plateau is biological adaptation.
What should I eat?
Adequate protein, fiber-rich vegetables, controlled refined carbs, minimal liquid calories.
Can I be on Mounjaro for years?
Long-term data is accumulating; SURMOUNT-4 showed maintenance with continued therapy.
Is Mounjaro or Zepbound better?
Same molecule, same doses; different FDA labels for diabetes vs obesity.
What if I gain back weight on Mounjaro?
Review with your prescriber for cause and adjustment.
When should I switch medications?
Consider after 12+ weeks at max dose without adequate response.
Related guides
- Stopped Losing Weight on Ozempic? Plateau-After-Loss Patterns Explained
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
- Why Am I Not Losing Weight on Wegovy? The Six Levers Worth Pulling
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Why Am I Not Losing Weight on Tirzepatide? Decoding Stalled Progress
Sources
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Aronne LJ et al., "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity," JAMA, January 2024 (SURMOUNT-4)
- Mounjaro FDA prescribing information
- Zepbound FDA prescribing information
- Wilding JPH et al., STEP 1, NEJM 2021
- Tasali E et al., JAMA Internal Medicine, March 2022 (sleep extension trial)
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- American College of Endocrinology consensus statements on obesity
- American Thyroid Association guidance on hypothyroidism screening
- CDC alcohol use guidelines
- National Sleep Foundation duration guidance
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians for GLP-1 therapy evaluation. This article is educational and does not substitute for clinical care. Discuss your specific situation with your prescriber.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded tirzepatide is available through 503A pharmacy partners for patients with documented clinical justification. Not FDA-approved. SURMOUNT trial data applies to brand Mounjaro and Zepbound specifically.
Results Disclaimer. Individual outcomes vary. SURMOUNT-1 reported a 22.5% mean weight loss at 15 mg over 72 weeks; the distribution included substantial variation including a 14% modest-responder subset. Your result depends on dose, adherence, baseline weight, lifestyle, and individual physiology.
Trademark Notice. Mounjaro, Zepbound, and SURMOUNT are registered trademarks or service marks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →